WO2007100220A1 - Systeme de diagnostic en temps reel utilisant un procede non invasif pour analyser le champ electro-magnetique emanant d'un sujet et sa variation - Google Patents

Systeme de diagnostic en temps reel utilisant un procede non invasif pour analyser le champ electro-magnetique emanant d'un sujet et sa variation Download PDF

Info

Publication number
WO2007100220A1
WO2007100220A1 PCT/KR2007/001041 KR2007001041W WO2007100220A1 WO 2007100220 A1 WO2007100220 A1 WO 2007100220A1 KR 2007001041 W KR2007001041 W KR 2007001041W WO 2007100220 A1 WO2007100220 A1 WO 2007100220A1
Authority
WO
WIPO (PCT)
Prior art keywords
frequency
biosensor
measured
subject
circuit
Prior art date
Application number
PCT/KR2007/001041
Other languages
English (en)
Inventor
Sang-Moon Lee
Original Assignee
Sang-Moon Lee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sang-Moon Lee filed Critical Sang-Moon Lee
Priority to US12/280,766 priority Critical patent/US20090137895A1/en
Priority to JP2008557212A priority patent/JP5155193B2/ja
Priority to EP07715450A priority patent/EP1996074A4/fr
Publication of WO2007100220A1 publication Critical patent/WO2007100220A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/05—Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves 
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23C—MILLING
    • B23C3/00—Milling particular work; Special milling operations; Machines therefor
    • B23C3/12—Trimming or finishing edges, e.g. deburring welded corners
    • B23C3/126—Portable devices or machines for chamfering edges
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23C—MILLING
    • B23C2220/00—Details of milling processes
    • B23C2220/16—Chamferring
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B23—MACHINE TOOLS; METAL-WORKING NOT OTHERWISE PROVIDED FOR
    • B23C—MILLING
    • B23C2220/00—Details of milling processes
    • B23C2220/40—Using guiding means

Definitions

  • the present invention relates to a real-time disease diagnostic system by analyzing of an electromagnetic field radiated from a subject and variation thereof, and more particularly to a real-time disease diagnostic system employing a non-invasive method capable of analyzing a micro electro-magnetic field and variation thereof radiated from cells, tissues and organs of a subject (i.e., a living organism: hereinafter, referred to as a subject) .
  • the diagnostic system is able to diagnose a health condition of a subject suffering from various diseases caused by immunodeficiency including cancer which is one of proliferative diseases characteristic of an abnormal cell proliferation at an early stage in a more accurate and safe manner by indicating the state of the diseases as a numerical value, sounds or a three-dimensional image in real time without any of side effects.
  • a material for the detection of biological electromagnetic signals hereinafter, referred to as a biosensor
  • the devices for diagnosing the diverse diseases caused by immunodeficiency including cancer which is one of proliferative diseases characteristic of an abnormal cell proliferation have disadvantages in that the devices are so bulky that they can be spatially restricted, economical burdens to the subject needed to be diagnosed, an accuracy rate of diagnosing cancer is low, i.e. from about 30% to 50%, and especially, the accuracy rate of the measured cancer is far lower than the above range if a size of the cancer is less than lcm, and therefore it is so difficult to recognize the presence of cancer in an early stage.
  • the conventional diagnostic devices require the complicated doctor's orders for a subject (i.e., a living organism) in most cases before the diagnosis, i.e., an empty stomach or taking certain medicine or the like, and therefore a problem is that some diagnostic devices may cause side effects in an invasive method such as radiation penetration.
  • the diagnosis system of the present invention is made of a material for the detection of biological electromagnetic signals using specially processed bio-friendly biomaterials and the system may be medically examined by a doctor, or may be self-examined by a subject oneself according to the diagnostic site.
  • the system also may be used to conveniently diagnose the diseases without special doctor's orders prior to the diagnosis, operated at a low power, and used to determine the diseases outside the body using a non-invasive method. Therefore, an object of the present invention is to provide a diagnostic system capable of greatly decreasing any of side effects and dramatically increasing an accuracy in the early cancer diagnosis.
  • Another object of the present invention is to provide a diagnostic system capable of diagnosing various diseases caused by immunodeficiency as well as early cancer, and the data base of the patients obtained through a biosensor and a disease diagnostic system including the biosensor can make hospital staffs and a subject check the long-term progress of the disease in the patients and check the result of treatment in real time, if the patient is necessarily treated for a long time.
  • Yet another object of the present invention is to provide a diagnostic system, unlike measurement devices such as a magnetic resonance imaging (MRI) , X-Ray and computerized tomography (CT) using conventional magnetic resonance, being able to easily diagnose the presence and the kind of disease by analyzing the variation on electro-magnetic field radiated from an in vivo bio- action potential of the living organism, and the information obtained by biosensor and the system comprising the biosensor.
  • the in vivo bio-action potential inputted in the biosensor and the system comprising the biosensor is processed in an analog circuit, converted to digital signal, numerized to allow a user to analyze the converted signal through a suitable algorism and transmitted to a display panel or monitor of the device itself or to a personal computer (PC) .
  • PC personal computer
  • the diverse cancerous diseases may be diagnosed at an early stage, and simultaneously the results of examination may be stored in a database so that the development of the disease and the treatment result can be re-confirmed at any time. Therefore, diverse diseases such as cancer or inflammation could be diagnosed at an early stage and effectively treated and prevented the diverse diseases.
  • a real-time disease diagnostic system capable of analyzing an electromagnetic field radiated from a subject and variation thereof, the system including a sensor probe including at least one biosensor receiving a biological electro-magnetic field in a living organism including a human body and changing a capacitance; an analog circuit for processing a bio- action potential signal measured by the sensor probe into an analog signal; a digital conversion circuit for converting the analog signal outputted from the analog circuit and processing the converted analog signal; and a power circuit for supplying driving power to the system and charging a battery with power, a communication circuit for communicating with a PC, and a communication module for wirelessly communicating with the PC.
  • the analog circuit includes a multi-channel multiplexer for selecting a channel from the sensor probe; a sensor selection unit for selecting certain sensors among multi-channel sensors from the sensor probe and selecting a sensor for measurement from the certain sensors; a frequency controller for minimizing errors such as an error caused when a region of the biosensors of the sensor probe is composed of multiple channels, a basic manufacturing error of electronic components, and an environmental error of a measurement region and the like and adjusting a frequency generated in a frequency oscillation circuit to a reference frequency of the sensor accurately; a frequency generator for generating a reference frequency unique to the sensors based on the capacitance element when the biosensors in the sensor probe is in a normal state before their diagnosis; a frequency signal amplifier for amplifying level of a frequency signal generated from the frequency generator up to a level where the frequency signal is used in the digital conversion circuit; and a frequency allocator for allocating the frequency can be measured in the digital conversion circuit.
  • the digital conversion circuit includes a flash memory for storing measurement data and program data; a SDRAM used for a temporary memory area; a CPU for measuring the frequency and performing various operations; a PWM module comprising a switch circuit receiving a command from a user and a buzzer generating sounds according to an input frequency; a LCD for operating measured data and displaying the operated data on a graphic user interface (GUI) ; and a LCD inverter for controlling a brightness of the LCD.
  • GUI graphic user interface
  • the power circuit is free from the use of power supplied from a commercial power source, the power is supplied from a battery even though an adaptor is used for connection, and the power circuit is configured to feed back a voltage of the battery to the CPU by a battery charge measurement circuit in order to check a residual capacity and charged capacity of the battery.
  • the frequency signal amplifier converts a level of a frequency signal outputted through a RLC circuit in the frequency generator up to a level where the frequency signal can be measured in the digital conversion circuit.
  • the basic capacitance of the biosensor is in the range from 0.5pF to 90OpF, and more preferably from IpF to 40OpF.
  • a frequency of an oscillating circuit is determined according to the changes in the capacitance of the biosensor.
  • a value of the capacitance changed according to a value of the bio-action potential detected by the biosensor and inputted from a living body tissue of the subject is converted into a frequency or a voltage value for diagnosing a disease of the subject.
  • the health condition of the subject is determined according to a variation of a delta frequency which is a difference value between the reference frequency unique to the biosensor and the measured frequency detected by the biosensor.
  • the difference value between the reference frequency and the measured frequency is determined by determining a delta frequency using a clock of the CPU 11 supplied through an oscillator 10 and a voltage-frequency (VF) converter, measuring the frequency oscillated from the sensor, and comparing the measured frequency with the reference frequency.
  • VF voltage-frequency
  • the frequency from sensor using an A/D converter inside or outside of the CPU is passed through frequency-voltage (FV) converter to gain a voltage value.
  • the voltage value is converted to a digital value and measured frequency compared with the reference frequency to determine the difference value.
  • the reference frequency is a reference frequency for comparing with the measured frequency detected by the biosensor when the biosensor is free from the exposure to the bio-action potential, and is adjusted to the same frequency as the frequency unique to the biosensor.
  • the reference frequency of the sensor as the frequency unique to the biosensor has a frequency band from 0.5Hz to 95MHz, and more preferably from 10Hz to
  • the reference frequency is primarily calibrated in the analog circuit and secondarily adjusted to the same frequency as the frequency unique to the biosensor in consideration of the characteristics of the biosensor sensitive to measurement environments so that it can be adjusted by the digital conversion circuit and a given program.
  • the reference frequency that can be adjusted in an analog mode is in the range from 5Khz to lOMhz.
  • the reference frequency that can be adjusted in a digital mode is in the range from 0.1hz to lMhz .
  • an acquisition speed of the bio-action potential inputted from the biosensor is changed by the digital mode.
  • the health condition of the subject is classified into three types or more according to the measured value of the delta frequency, and represented by green, yellow, red color, or other diverse color indicators, respectively.
  • the health condition of the subject is classified into three types or more according to the measured value of the delta frequency and represented by green, yellow, red color, or other diverse color indicators, respectively, and, in the case of the subject suffering from cancer, the yellow and red indicators are randomly displayed on an LCD screen and displayed on a screen of a monitor of the PC to which data measured by the measurement device is transmitted.
  • the health condition of the subject is classified into three types or more according to the measured value of the delta frequency and represented by green, yellow, red color, or other diverse color indicators, respectively, and boundary values among green, yellow, red color and other various colors is controlled according to the purpose of use.
  • the health condition of the subject is classified into multiple types according to the measured value of the delta frequency and represented by a sound signal or an alarm sound that has different frequencies.
  • the disease diagnostic system is connected with the PC by means of a wireless LAN, a wireless communication module, a USB port or RS-232C, and the PC displays the data measured by the disease diagnostic system in the form of a three-dimensional graphic, multidimensional graphic or stereoscopic image.
  • the diagnostic result is indicated in the form of audio signal, alarm sound, a three-dimensional graphic, a multi-dimensional graphic or a stereoscopic image, however, in the case of a single channel, the diagnostic result is indicated in the form of a digital numerical value and the audio signal or alarm sound.
  • the disease diagnostic system is connected with the PC by a wireless communication module (LAN, Bluetooth, Zigbee) , a USB port or RS 232C, and the PC stores the data measured by the disease diagnostic system into the database.
  • a wireless communication module LAN, Bluetooth, Zigbee
  • a USB port or RS 232C
  • the disease diagnostic system has advantages, as follows .
  • the disease diagnostic system of the present invention may be useful to measure the bio-action potential signal using a single- or multi-channel biosensor, and promptly and accurately diagnose a health condition of the corresponding diagnostic region of a subject, in particular the presence of the disease such as cancer which is one of proliferative diseases characteristic of an abnormal cell proliferation in a manner, on the basis of the measured data.
  • the conventional cancer diagnostic device requires many doctor's orders for a subject before the diagnosis, however, the disease diagnostic system of the present invention requires no limitations observed before the diagnosis, and may be useful to diagnose various diseases within a short time range from 10 minutes to 1 hour employing the non-invasive method without any of the limitations and side effects such as a vomiting symptom caused by the radiation exposure and medicine injections. Also, the disease diagnostic system of the present invention may be manufactured with low power consumption and a smaller size so that the health condition of the person in need can be diagnosed anytime and anywhere in a prompt and simple manner, thereby indicating the realtime diagnostic results in the form of the numerical value, audio sounds or three-dimensional image.
  • the disease diagnostic system of the present invention may be useful to diagnose various diseases such as cancer which is one of proliferative diseases characteristic of an abnormal proliferation of the various cells and diverse diseases caused by immunodeficiency at an early stage.
  • the disease diagnostic system of the present invention may be useful to re-confirm the development and treatment of the diseases at any time since every diagnosis result can be stored into the database.
  • FIG. 1 is a block diagram illustrating a real-time disease diagnostic system employing a non-invasive method by analyzing an electromagnetic field, and variation thereof, radiated from a subject according to the present invention.
  • FIG. 2 is a block diagram illustrating a digital conversion circuit of the disease diagnostic system as shown in FIG. 1.
  • FIG. 3 is a block diagram illustrating a sensor probe and an analog circuit of the disease diagnostic system as shown in FIG. 1.
  • FIG. 4 is a block diagram illustrating a power circuit of the disease diagnostic system as shown in FIG. 1.
  • FIG. 5 is a table illustrating a measurement order by a biosensor with a single channel (one channel) or multiple channels (five channels) .
  • FIG. 6 is a flowchart illustrating a process of measuring a frequency using a clock of the CPU according to the present invention.
  • FIG. 7 is a flowchart illustrating a process of measuring a frequency using an A/D converter inside the CPU according to the present invention.
  • FIG. 8 is an exemplary waveform view showing the frequency generated from a frequency generator of the analog circuit.
  • FIG. 9 is a diagram showing a clock of the CPU corresponding to an input frequency.
  • FIG. 10 is a block diagram illustrating a frequency oscillation circuit and its peripheral circuits.
  • FIG. 11 is a flowchart illustrating a process of setting a channel frequency using a frequency controller.
  • FIG. 12 is a graph illustrating that a subject is diagnosed to be in a very normal state using the disease diagnostic system according to the present invention.
  • FIG. 13 is a graph illustrating that a subject is diagnosed to be in a normal state using the disease diagnostic system according to the present invention.
  • FIG. 14 is a graph illustrating that a subject is diagnosed to be in an inflammatory state using the disease diagnostic system according to the present invention.
  • FIG. 15 is a graph illustrating that a subject is diagnosed to be in a cancerous state using the disease diagnostic system according to the present invention.
  • FIG. 16 is an example that a diagnostic result by the biosensor is indicated in the form of a three- dimensional graphics on a personal computer.
  • FIG. 17 is a flowchart illustrating a measurement method in a case of a prescan mode among measurement modes according to the present invention.
  • FIG. 18 is a flowchart illustrating a measurement method in the case of a precise mode among measurement modes according to the present invention.
  • FIGs. 19 through 24 are exemplary views showing an image of Experimental examples .
  • FIG. 25 is a graph illustrating the changes of body weight in nude mice transplanted human cancer cell lines.
  • FIG. 26 is a graph illustrating the changes of tumor volumes in nude mice transplanted human cancer cell lines .
  • FIG. 27 is a graph illustrating the changes of tumor volumes in nude mice transplanted human lung cancer cell lines (G2; A549) .
  • FIG. 28 is a graph illustrating the changes of tumor volumes in nude mice transplanted human colon cancer cell lines (G3; HCT15) .
  • FIG. 29 is a graph illustrating the changes of tumor volumes in nude mice transplanted human melanoma cancer cell lines (G4; LOX-IMVI) .
  • FIG. 30 is a graph illustrating the changes of tumor volumes in nude mice transplanted human prostate cancer cell lines (G5; PC-3) .
  • FIG. 31 is a graph illustrating the changes of tumor volumes in nude mice transplanted human breast cancer cell lines (G6; MDA-MB-231) .
  • FIG. 32 is a graph illustrating tumor weight in nude mice transplanted human lung cancer cell lines (G2; A549) on the 21 st day of the experiment.
  • FIG. 33 is a graph illustrating tumor weight in nude mice transplanted human colon cancer cell lines (G3; HCT15) on the 21 st day of the experiment.
  • FIG. 34 is a graph illustrating tumor weight in nude mice transplanted human melanoma cancer cell lines (G4; LOX-IMVI) on the 21 st day of an experiment.
  • FIG. 35 is a graph illustrating tumor weight in nude mice transplanted human prostate cancer cell lines (G5; PC-3) on the 21 st day of an experiment.
  • FIG. 36 is a graph illustrating tumor weight in nude mice transplanted human breast cancer cell lines (G6; MDA-MB-231) on the 21 st day of an experiment.
  • FIG. 37 is a picture illustrating well differentiated carcinoma of the lung cancer.
  • FIG. 38 is a picture illustrating manifest mitotic and gangrenous carcinoma of the colon cancer.
  • FIG. 39 is a picture illustrating gangrenous, undifferentiated and pleomorphic carcinoma of the melanoma.
  • FIG. 40 is a picture illustrating insufficiently differentiated but manifest gangrenous and pleomorphic carcinoma of the prostate cancer.
  • FIG. 41 is a picture illustrating insufficiently differentiated but sufficiently mitotic solid carcinoma of the breast cancer.
  • sensor probe 2 analog circuit
  • flash memory 12a flash memory 12a: ROM selector
  • PWM module 16a frequency control oscillator
  • USB port 19c RS-232C
  • battery charging circuit 34 battery 35: 3.3 volt regulator
  • a real-time disease diagnostic system employing a non-invasive method capable of analyzing a micro electromagnetic field, and variations thereof, radiated by a bio-action potential from cells, tissues and organs of a subject senses a micro electromagnetic field and variations thereof radiated by a bio-action potential from cells, tissues and organs of a subject as a capacitance and variations thereof using a biosensor, analyses a frequency obtained according to the capacitance and variations thereof to diagnose diverse diseases caused by immunodeficiency including cancer which is one of proliferative diseases characteristic of an abnormal cell proliferation.
  • FIG. 1 is a block diagram illustrating the real- time disease diagnostic system employing the non-invasive method capable of analyzing the electro-magnetic field and variations thereof radiated from the subject according to the present invention.
  • the disease diagnostic system according to the present invention includes a sensor probe 1 comprising at least one biosensor receiving a biological electro-magnetic field in a living organism including a human body and changing a capacitance; an analog circuit 2 for processing a bio- action potential signal measured by the sensor probe into an analog signal; a digital conversion circuit 3 for converting the analog signal outputted from the analog circuit 2 and processing the converted analog signal; and a power circuit 4 for supplying driving power to the system and charging a battery with power, a communication circuit for communicating with a PC, and a communication module 19 for wirelessly communicating with the PC as shown in FIG.
  • biosensor constituting the sensor probe 1 is disclosed in the Korean Patent Application No. 10- 2006-0013170 filed on February 10, 2006 entitled “SENSOR FOR DETECTING BIOLOGICAL ELECTRO-MAGNETIC SIGNAL AND THE DIAGNOSTIC DEVICE USING THE SAME" filed by the same applicant of the present invention prior to filing this subject matter.
  • the bio-action potential signal is generated by the bio-action potential from cells, tissues, organs and the like, of a living organism.
  • An epidermal tissues of an animal have functions of sensing, memorizing and transmitting a extreme precision the enormous subtle minute information signal (bio-action potential signal) of the electro-magnetic field.
  • bio-action potential signal a scale of a fish, a scale of a reptile, a carapace of a crustacean, a cuticle of an insect species or the like is used to make an biosensor.
  • the biosensor serves to respond to a bio- action potential signal and variations thereof and transmit and retransmit the signal and variations thereof, radiated by the bio-action potential from cells, tissues, organs and the like, of the living organism.
  • the bio-action potential signal sensed by the sensor probe 1 is analyzed by an algorism stored in the analog circuit 2 and the digital conversion circuit 3 and the analyzed signal is indicated in the form of three diagnostic indicators, i.e., the green or yellow indicator is displayed on a screen if there is no certain abnormal change in the bio-action potential signal, whereas the red indicator is displayed on a screen if there is a certain abnormal change in the bio- action potential signal (i.e., inflammations, etc).
  • the bio-action potential signal inputted by the sensor probe 1 is randomly displayed on a screen with the mixed indicators of yellow, red and other colors by the algorisms that are set in the analog circuit 2, the digital conversion circuit 3 and the CPU program in the digital conversion circuit 3, then it may be diagnosed as a cancer
  • researchers or the subject can recognize the state of the diagnosed region through an auditory sense by varying a range of the frequency applied to the buzzer 16b whenever the final result is changed into green, yellow or red colors.
  • the biological electro-magnetic signal inputted into the sensor probe 1 is processed by the analog circuit 2, the digital conversion circuit 3 and so on, it can be transmitted to the PC by a wired/wireless communication module so that relevant data such as a diagnosed region, a diagnosis result and a clinical history can be classified as unique to the subject and stored in the database of the PC.
  • a principle of the method for diagnosing cancer at an early stage using the real-time disease diagnostic system capable of analyzing the electromagnetic field and variations thereof radiated from the subject according to the present invention is that the basic capacitance of the biosensor in the disease diagnostic system is in the range of 0.5pF to 90OpF, and more preferably IpF to 40OpF according to the purpose of fabricating the biosensor, and the biosensor capacitance is varied according to the bio-action potential signal (electromagnetic field) inputted to the biosensor.
  • the disease diagnostic system of the present invention may measure variation factors of the capacitance of the biosensor changed according to the bio-action potential signal, and diagnose the health condition of the subject based on the variation factors.
  • the disease diagnostic system includes a sensor probe 1, an analog circuit 2, a digital conversion circuit 3 and a power unit 4, as shown in FIG. 1.
  • the above-mentioned digital conversion circuit 3 includes a CPU 11, a flash memory 12, a SDRAM 13, a frequency input unit 17, a channel selection unit 18 and the like, as shown in FIG. 2.
  • the analog circuit 2 includes a multi-channel multiplexer 22, a sensor selection unit 23, a frequency controller 24, a frequency generator 25, a frequency signal amplifier 26, a frequency allocator 27 and the like, as shown in FIG. 3.
  • the disease diagnostic system according to the present invention further includes a LCD 15 for displaying an operation state or diagnostic results, a LCD inverter 14, a PWM module 16, and a PC or a communication module 19 for communicating with the outside .
  • the frequency generator 25 of the analog circuit 2 generates a frequency as the reference frequency unique to the sensor on the basis of capacitance elements when the biosensor in the sensor probe 1 is in a normal state before the diagnosis, as shown in FIG. 8.
  • the reference frequency is controlled through the frequency controller 24 when the biosensor of the sensor probe 1 is in a steady state.
  • the biosensor of the sensor probe 1 may be fabricated with the various forms spanning from a single channel to multiple channel, as shown in FIG. 3.
  • a multi-channel multiplexer 22 for selecting a channel from the sensor probe 1 and the sensor selection unit 23 for selecting a sensor from the sensor probe 1 should be included in the system.
  • the frequency signal amplifier 26 amplifies the extreme precision the enormous subtle minute signal up to a level that can be used in the digital conversion circuit 3.
  • the signal amplified by the frequency amplifier 26 is a rapid frequency on the order of several MHz range, which is then allocated by the frequency allocator 27 so that it can be measured in the digital conversion circuit 3.
  • the frequency signal process as above is inputted into the frequency input unit 17 and the channel selection unit 18 in the digital conversion circuit 3 shown in FIG. 2.
  • the frequency signal inputted into the CPU 11 by the frequency input unit 17 is calculated as a frequency value by the CPU 11.
  • the value of the basic capacitance of the biosensor is varied slightly during the process for manufacturing the sensor probe 1. Accordingly, although the value of the reference frequency is adjusted in the analog circuit 2 as shown in FIG. 8, the value of the basic frequency may be varied slightly due to the change in the capacitance value. Therefore, a process of reference frequency control is carried out according to an algorithm shown in FIG. 11.
  • channels are selected by the channel frequency selection unit 18, the reference frequency of a material for the detection of biological electromagnetic signals (biosensor) for each channel is set by using the frequency control oscillator 16a, and then the CPU 11 stores sequentially voltage value of each channel to each channel in memory areas of the SDRAM 13. That is, the change value in the PWM data is discriminated in sequence until the reference frequency coincides with the obtained channel frequency.
  • the stored data is outputted to the digital frequency controller whenever frequencies are read from the data in each of the channel of the sensor, and the above-mentioned operation is sequentially repeated.
  • the difference of the delta frequency in the reference frequency is generated, as shown in FIG. 8.
  • the CPU 11 measures the difference between the frequencies, i.e., the value of the delta frequency, and controls the operation of the frequency controller 16a to adjust the frequency applied to the buzzer 16b in such a manner that the buzzer 16b can generate different sounds according to the value of the delta frequency.
  • the delta frequency means a frequency that is changed when the biosensor starts to measure the frequency (when it is in an open state, it is set to the reference frequency) . According to the present invention, there are two methods for measuring the above-mentioned delta frequency.
  • A/D converter not shown
  • F-V frequency-voltage
  • the CPU 11 determines which color among green, yellow and red is displayed according to the value of the delta frequency. At this time, the CPU 11 allocates a region where data may be stored in a region of the flash memory 12 and stores the measured delta frequency in the allocated region. Accordingly, the LCD 15 selectively outputs green, yellow and red colors which are determined by the CPU 11 according to the value of the delta frequency.
  • the LCD inverter 14 controls brightness of the LCD 15.
  • the CPU 11 is connected with a wireless communication module 19a and a communication module 19 including a USB port 19b and RS-232C 19c so that it can transmit the value of the delta frequency to the PC.
  • the data transmitted to the PC using various communication schemes are displayed in the form of a three-dimensional graphics as shown in FIG. 16, or can be stored, outputted and stored into the database, by using a given program.
  • the value of the capacitance is converted into a value of the frequency by using a frequency oscillation circuit 20.
  • the frequency controller 24 includes the frequency oscillation circuit 20, a low pass filter 21 and a PWM module 16 as shown in FIG. 10.
  • the frequency oscillation circuit 20 oscillates a reference frequency unique to the sensor of FIG. 8 when the biosensor of the sensor probe 1 is in a steady state, i.e., not in contact with the bio-action potential signal as shown in FIG. 5, the reference frequency being identical to the frequency value.
  • the biosensor is highly sensitive to the external environments, and therefore the frequency of the signal outputted through the frequency oscillation circuit 20 is also sensitively changed if the external environments are changed. Accordingly, the biosensor should be necessarily fixed at a uniform frequency under any of the environments when the biosensor is in an open state, i.e., when the biosensor does not measure a frequency.
  • the frequency controller 24 is provided for minimizing errors such as an error caused when a region of the biosensors of the sensor probe 1 is composed of multiple channels, a basic manufacturing error of electronic components, and an environmental error of a measurement region and the like and adjusting a frequency generated in a frequency oscillation circuit 20 to a reference frequency of the sensor accurately.
  • the bio-action potential signal of the subject i.e. the living organism
  • the value of the capacitance of the biosensor is changed (increased) as the biosensor receives the biological electromagnetic field within the living organism including the human body as described above, so that the frequency is also changed.
  • the value of the capacitance is increased, the frequency f generated from the frequency oscillation circuit 20 is decreased according to a basic principle of a formula of
  • the frequency signal amplifier 26 amplifies a signal up to a certain signal level that may be measured by the digital conversion circuit 3.
  • the frequency signal amplifier 26 serves to convert the frequency signal level up to a signal level of OV to 5V and into a square wave, that may be measured in the digital converting circuit 3, since a frequency signal level outputted through the RLC circuit in the frequency generator 25 is displayed in a form of a sine wave of 1.2V to 2.2V, which is not adequate for the digital input signal used for measuring the frequency of the signal .
  • the biosensor of the sensor probe 1 is composed of many channels spanning from a single channel to multiple channels, and therefore a multi-channel multiplexer 22 and a sensor selection unit 23 are used to measure all of the multiple channels.
  • the measurement order of the biosensor that senses the bio-action potential signal using the multi-channel multiplexer 22 and the sensor selection unit 23 is as FIG. 5.
  • the frequency allocator 27 allocates the frequency oscillated by the frequency oscillation circuit 20.
  • the digital conversion circuit 3 includes the flash memory 12 for storing a measured data and a program data, the SDRAM 13 used for a temporary memory area, the CPU 11 for measuring a frequency and performing diverse operations, the PWM module 16 including a switch circuit for inputting a command from a user (not shown) and a buzzer 16b for generating sounds according to an input frequency, the LCD 15 for operating the measured data and displaying the operated data on a graphic user interface (GUI) , and the LCD inverter 14.
  • GUI graphic user interface
  • the digital conversion circuit 3 needs a frequency measurement algorithm for measuring final frequencies outputted from the analog circuit 2.
  • the clock of the CPU 11 is counted for one period of the clock signal of the reference frequency of the material for the detection of biological electromagnetic signals (of the biosensor of FIG. 8) shown in FIG. 9, inputted through an input/output module of the CPU 11.
  • the frequencies (F) are measured according to following Formula:
  • the frequency oscillation circuit 20 oscillates the basic frequency.
  • 2 ⁇ slLxC delta frequency can be obtained by deducting the decreased frequency from the basic frequency.
  • the delta frequency indicates the amount of biological electromagnetic signals. Accordingly, an increase in the delta frequency indicates a large amount of biological electromagnetic signals, whereas a decrease in the delta frequency indicates a small amount of biological electromagnetic signals.
  • the delta frequency is classified into three states.
  • a first state where the bio-action potential is in a general motion state
  • a second state where the bio-action potential is in an active state
  • a third state where the bio-action potential is in a very active or pulsatory state.
  • the respective three states are displayed as follow: "green” indicating an excellent health condition of a subject; “yellow” indicating a good health condition / and “red” indicating an inflammation or a bad health condition. That is, if the bio-action potential is in the first state, “green” is indicated on the LCD 15 of the disease diagnostic system according to the present invention or on the screen of the PC, “yellow” is indicated if the bio-action potential is in the second state, and “red” is indicated if the bio-action potential is in the third state.
  • the basic frequency generated in the frequency generator 25 by the frequency controller 24 is adjusted to the reference frequency of the frequency controller 24 shown in FIG. 3 and the biosensor shown in FIG. 8.
  • the reference frequency is not maintained accurately and is varied minutely in the procedure of receiving a reference frequency from the digital conversion circuit 3 and operating the received reference frequency.
  • the frequency control oscillator 16a is also provided in the digital conversion circuit 3 to cope with such a phenomenon as well as control the frequency precisely.
  • a frequency setting unit includes the sensor probe 1 having a material for the detection of biological electromagnetic signals, the frequency oscillation tuning circuit 20, the low pass filter 21, the CPU 11 having input and output ports, the PWM module 16, the flash memory 12 or the like.
  • the CPU 11 receives a frequency from the analog circuit 2 to confirm the reference frequency. If the measured frequency is different from the reference frequency, the CPU 11 executes an adjustment algorism on the measured frequency.
  • the bio-action potential signal of the subject i.e., the living organism is measured using the disease diagnostic system including the biosensor according to the present invention
  • "green” and “yellow” as shown in FIGs. 12 and 13 are maintained in a constant state if the subject is excellent or good in health
  • "red” as shown in FIG. 14 is maintained in a constant state if the subject is bad in health due to an inflammation, etc.
  • the indicator states are unstable as in “red” in FIG. 14, "yellow” in FIG. 13, “red” in FIG. 14, “yellow” in FIG. 13, and “green” FIG. 12 and the indicator state is irregular as shown in FIG. 15.
  • the degree of the irregularity i.e., the change width of the delta frequency is different according to the individuals or the state of cancer.
  • FIG. 17 illustrates a channel draw mode which reads material
  • FIG. 18 illustrates a precise mode which reads material
  • the prescan mode as shown in FIG. 17 illustrates a process of continuously transmitting the measured data until the user presses a stop button or the PC gives a stop command when a break signal is inputted.
  • the precision mode as shown in FIG. 18 illustrates the process of sending all data in the multichannel biosensor ten times and then standing by until the user presses a button for measurement .
  • the measured data as described above is displayed on the LCD 15 mounted in the PC or the disease diagnostic system.
  • the delta frequency value of the measured frequency "green (in FIG. 10)", “yellow (in FIG. 11)” and “red (in FIG. 12)" are displayed according to the method as described above. Then, they are displayed in the form of the three-dimensional graphics on the PC, as shown in FIG. 16.
  • the standard of the difference value of the frequency classifying "green”, “yellow” and “red” is set on the basis of the results obtained by carrying out pre- animal clinic tests several hundreds times, which was conducted in "UNI Bio-Tec” company.
  • the reference frequency is 50.40 KHz.
  • a mouse is very good in health so "green” is indicated if the measured frequency is within the range from 50.40 to 48.38 KHz
  • the mouse is good in health so “yellow” is indicated if the measured frequency is within the range from 48.37 to 46.79 KHz
  • the mouse is inflammatory so “red” is indicated if the measured frequency is less than 46.78 KHz. If “yellow” and “red” are irregularly indicated, it is judged to be cancer.
  • the transmitted data is transmitted according to a specific data transmission protocol by the wireless communication module 19a, the USB port 19b and the RS-232C 19c of the PC or diagnostic device.
  • the power circuit 4 of FIG. 1 is also shown in FIG. 4, and includes the adaptor 31, the battery charge measurement circuit 32, the battery charging circuit 33, the battery 34, the 3.3 volt regulator 35, the 2.5volt regulator 36, the 5 volt regulator 37 and the like. 3.3 volt and 2.5 volt are supplied to the digital conversion circuit 3 and 5 volt is supplied to the analog circuit 2.
  • the battery 34 is implemented with a Nickel Metal Hybrid (Ni-MH) battery, which has a capacitance of about 1200mA/H and thus can power the diagnostic device of the invention at a current of 55OmA for about 2 hours.
  • Ni-MH Nickel Metal Hybrid
  • the diagnostic device of the invention is a medical device and thus does not directly use a commercial or common voltage to ensure safety for a subject (living organism) . Even though the adaptor 31 is used, the diagnostic device is powered from the battery 34. To check the residual capacity and charged capacity of the battery 34, the voltage of the battery 34 is fed back to the CPU 11 by the battery charge measurement circuit 32.
  • the measurement of cancer diagnostic performances using "functions of a biosensor of a early cancer diagnostic device and the early cancer diagnostic device" in a nude mouse transplanted with a cancer cell is conducted by Pre-Clinical Research Center (KGLP Approval) of Chemon Inc .
  • This experiment is implemented to evaluate a performance (effect) of a newly developed early cancer diagnostic device (a biosensor of the early cancer diagnostic device and the early cancer diagnostic device diagnostic device) for a purpose of diagnosing cancer at early stage in a nude mouse transplanted with a human cancer cell.
  • Specific pathogen free (SPF) Athymic BALB/C nude mice, which were 8 weeks old and females, were used as the species and cell line of a testing system in this experiment .
  • Test mice were grouped into six subcutaneous transplanted groups, each of which includes 10 mice, wherein the grouping being carried out by arranging the mice in order of their weight measured on the day that the mice is transplanted with the cancer cell .
  • the mouse populations were identified using an identification label on a breeding cages and an ear punch method. However, the mouse populations were reared regardless of their groups during the experiment period, and a inventor of the present invention was not informed of the transplanted carcinoma. Test groups are as reported in Table 1 below: TABLE 1
  • Gl Control group where cancer cells are not transplanted
  • G2 to G6 Cancer groups where cancer cells are transplanted
  • This experiment is implemented to evaluate a performance of a newly developed early cancer diagnostic device (a biosensor of the early cancer diagnostic device and the early cancer diagnostic device diagnostic device) for a purpose of diagnosing cancer at early stage in a nude mouse transplanted with a human cancer cell, by using the "early cancer diagnostic device" according to the present invention.
  • the tests of the early cancer diagnostic device were implemented using the early cancer diagnostic device being manufactured with functions of the biosensor developed by the inventor of the present invention.
  • the inventor of the present invention randomly measured carcinogenesis in the animals by group from the first day of the cancer cells transplantation under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc., and Chemon measured a tumor volume from 8 th day after the transplantation when it is able to measure a size of the transplanted cancer cell.
  • the functions of the biosensor and the diagnostic performances of the early cancer diagnostic device manufactured with the functions of the biosensor were compared and evaluated by comparing the experimental results measured by the inventor of the present invention and the Chemon Inc.
  • the subcutaneously transplanted mouse group was tested through the total 656 experiments for three weeks using the diagnostic device manufactured with the functions of the biosensor.
  • hits were 166 (87.4%) out of the total 190 experiments for the first seven days after the transplantation and there was no one hit out of the total 190 experiments in which the healthy mice were diagnosed to be cancerous.
  • hits were 629 (95.9%) out of the total 656 experiments and there was no one hit out of the total 656 experiments in which the healthy mice were diagnosed to be cancerous .
  • the kind of cancer cells were a human cancer cell line such as lung cancer (A549) , colon cancer (HCT15) , melanoma (LOX-IMVI), prostate carcinoma (PC-3) , and breast cancer (MDA-MB-231) , which were all obtained from the Korea Research Institute of Bioscience & Biotechnology in the form of freezing vials, and kept in a liquid nitrogen tank in a cell culture room of Pharmacology and Medicine Laboratory in the Pre-Clinical Researching center (KGLP Approval) of Chemon Inc., and each of the cancer cell lines were thawed at a 37°C in a water bath as soon as possible.
  • the thawed cancer cell lines were uniformly mixed in 5ml of a RPMI1640 culture containing 10% FBS
  • the cultured cancer cell was diluted in the physiological saline as IXlO 7 cells/ml density and injected 0.3 ml/mice as a route of subcutaneous.
  • the control group was injected with the same quantity and route with the saline.
  • the tumor volume was continuously measured using vernier calipers during a period from the 8 th day to the
  • Tumor Volume (mm 3 ) long diameter x short diameter x height/2
  • mice The hypodermic tumor was extracted from all the mice on an autopsy day. As a result, it was seen that the tumors were induced in all of the mice, and their histopathological examination showed that the induced tumors were proven to be cancer. When common symptoms were observed, no special symptoms were found from the animals except for those symptoms specific to cancer growth. In the group where melanoma was transplanted, mice died by one, respectively, on the 15 th and 18 th days.
  • the initial diagnosis and the presence of cancer were measured using the early cancer diagnostic device manufactured with the functions of the biosensor.
  • the inventor of the present invention measured carcinogenesis in the animals by group from the first day of the cancer cell transplantation under the pre-clinical test regulations of the Pre-Clinical Research Center (KGLP Approval) of Chemon Inc. by using the early cancer diagnostic device manufactured with the functions of the biosensor.
  • the Chemon measured a tumor volume from 8 th day after the transplantation when it is able to measure a size of the transplanted cancer cell.
  • the experimental results measured by the inventor of the present invention and the Chemon Inc. were compared with each other to calculate a diagnostic accuracy of the early cancer diagnostic device manufactured with the functions of the biosensor.
  • the tumor was induced in all of the subcutaneously transplanted animals (100%) , and was proven to be pathologically cancer.
  • the accuracy calculated using the early cancer diagnostic device manufactured with the functions of the biosensor was 95.9%, and there was no one experiment in which the control group (healthy mice) was diagnosed to be cancer.
  • hits were 166 out of the total 190 experiments for the first seven days after the transplantation, which showed a accuracy of 87.4%. According to the overall results, hits were 629 out of the total 656 experiments, which showed a accuracy of 95.9%. And, there was no one hit out of the total 656 experiments in which the healthy mice were diagnosed to be cancer.
  • FIG. 25 illustrates the changes of body weight in nude mice transplanted human cancer cell lines.
  • the cancer cells were transplanted using a hypodermic transplantation method, and the change in body weight were measured at the same time when a mouse was transplanted with the cancer cells.
  • FIG. 26 illustrates the changes of tumor volumes in nude mice transplanted human cancer cell lines. Here, a tumor size was measured from the 8 th day after the transplantation of the human cancer cell.
  • FIG. 27 illustrates the changes of tumor volumes in nude mice transplanted human lung cancer cell lines (G2; A549) .
  • a tumor size was measured from the 8 th day after the transplantation of the cancer cell, the cancer cell was diluted in saline to a density of lxl ⁇ 7 cells/ml, and an amount of the administered solution was 0.3ml.
  • the numbers as shown in the right legend on the graph are Nos . of the measured mice .
  • FIG. 28 illustrates the changes of tumor volumes in nude mice transplanted human colon cancer cell lines (G3; HCT15) .
  • a tumor size was measured from the 8 th day after the transplantation of the cancer cell, the cancer cell was diluted in saline to a density of lxl ⁇ 7 cells/ml, and an amount of the administered solution was 0.3ml.
  • the numbers as shown in the right legend on the graph are Nos . of the measured mice .
  • FIG. 29 illustrates the changes of tumor volumes in nude mice transplanted human melanoma cancer cell lines (G4 ; LOX-IMVI) .
  • a tumor size was measured from the 8 th day after the transplantation of the cancer cell, the cancer cell was diluted in saline to a density of lxl ⁇ 7 cells/ml, and an amount of the administered solution was 0.3ml.
  • the numbers as shown in the right legend on the graph are Nos. of the measured mice.
  • FIG. 30 illustrates the changes of tumor volumes in nude mice transplanted human prostate cancer cell lines (G5; PC-3) .
  • a tumor size was measured from the 8 th day after the transplantation of the cancer cell, the cancer cell was diluted in saline to a density of lxl ⁇ 7 cells/ml, and an amount of the administered solution was 0.3ml.
  • the numbers as shown in the right legend on the graph are Nos. of the measured mice.
  • FIG. 31 illustrates the changes of tumor volumes in nude mice transplanted human breast cancer cell lines (G6; MDA-MB-231) .
  • a tumor size was measured from the 8 th day after the transplantation of the cancer cell, the cancer cell was diluted in saline to a density of lxl ⁇ 7 cells/ml, and an amount of the administered solution was 0.3ml .
  • the numbers as shown in the right legend on the graph are Nos . of the measured mice .
  • FIG. 32 illustrates tumor weight in nude mice transplanted human lung cancer cell lines (G2; A549) on the 21 st day of the experiment. Autopsy of the mice was performed on the 21 st day of the experiment.
  • FIG. 33 illustrates tumor weight in nude mice transplanted human colon cancer cell lines (G3; HCT15) on the 21 st day of the experiment. Autopsy of the mice was performed on the 21 st day of the experiment.
  • FIG. 34 illustrates tumor weight in nude mice transplanted human melanoma cancer cell lines (G4; LOX- IMVI) on the 21 st day of the experiment. Autopsy of the mice was performed on the 21 st day of the experiment.
  • FIG. 35 illustrates tumor weight in nude mice transplanted human prostate cancer cell lines (G5; PC-3) on the 21 st day of the experiment. Autopsy of the mice was performed on the 21 st day of the experiment.
  • FIG. 36 illustrates tumor weight in nude mice transplanted human breast cancer cell lines (G6 ; MDA-MB- 231) on the 21 st day of the experiment. Autopsy of the mice was performed on the 21 st day of the experiment.
  • FIGs. 37 through 41 illustrate histopathological findings in nude mice transplanted human cancer cell lines.
  • FIG. 37 illustrates well differentiated carcinoma of the lung cancer.
  • FIG. 38 illustrates manifest mitotic and gangrenous carcinoma of the colon cancer.
  • FIG. 39 illustrates gangrenous, undifferentiated and pleomorphic carcinoma of the melanoma.
  • FIG. 40 illustrates insufficiently differentiated but manifest gangrenous and pleomorphic carcinoma of the prostate cancer.
  • FIG. 41 illustrates insufficiently differentiated but sufficiently mitotic solid carcinoma of the breast cancer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medical Informatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Mechanical Engineering (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)

Abstract

L'invention concerne un système de diagnostic de maladies en temps réel utilisant un procédé non invasif capable d'analyser un champ électromagnétique et ses variations émanant d'un sujet. Le système de diagnostic de maladies détecte un champ micro-électromagnétique et ses variations émanant du potentiel bioactif du tissu vivant, tel que des cellules, des tissus, des organes et analogues d'un sujet, comme une capacité et ses variations au moyen d'un biodétecteur à un ou plusieurs canaux. Le système de diagnostic de maladies comprend le biodétecteur. Ledit système analyse la fréquence obtenue par la capacité et ses variations et diagnostique une caractéristique des maladies prolifératives d'une prolifération cellulaire anormale, grâce au diagnostic de la totalité du corps au moyen d'un procédé non invasif dans une période courte, comprise entre 10 minutes et 1 heure, sans effet secondaires. Le système de diagnostic de maladies affiche le résultat du diagnostic sous la forme d'une valeur numérique, d'un son ou d'une image tridimensionnelle en temps réel. Le système peut être utilisé sans condition particulière prescrite par un médecin pour le patient, comme par exemple, le fait que le patient doit être à jeun ou qu'il doit avoir pris des médicaments, et il est utilisé pour confirmer facilement la disparition d'une cellule cancéreuse grâce à la chirurgie et au processus de traitement. Le système de l'invention peut être utilisé pour diagnostiquer de nombreuses maladies à un stade précoce, de manière plus précise et sûre.
PCT/KR2007/001041 2006-03-02 2007-03-02 Systeme de diagnostic en temps reel utilisant un procede non invasif pour analyser le champ electro-magnetique emanant d'un sujet et sa variation WO2007100220A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US12/280,766 US20090137895A1 (en) 2006-03-02 2007-03-02 Real-time diagnostic system employing non-invasive method to analyze electro-magnetic field radiated from a subject and the variation thereof
JP2008557212A JP5155193B2 (ja) 2006-03-02 2007-03-02 被検対象者から放射される電磁気場とその変化量分析による非侵襲的方法の実時間疾病診断システム
EP07715450A EP1996074A4 (fr) 2006-03-02 2007-03-02 Systeme de diagnostic en temps reel utilisant un procede non invasif pour analyser le champ electro-magnetique emanant d'un sujet et sa variation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020060020099A KR100794721B1 (ko) 2006-03-02 2006-03-02 피검 대상자로부터 방사되는 전자기장과 그의 변화량분석에 의한 비침습적방법의 실시간 질병 진단시스템
KR10-2006-0020099 2006-03-02

Publications (1)

Publication Number Publication Date
WO2007100220A1 true WO2007100220A1 (fr) 2007-09-07

Family

ID=38459285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2007/001041 WO2007100220A1 (fr) 2006-03-02 2007-03-02 Systeme de diagnostic en temps reel utilisant un procede non invasif pour analyser le champ electro-magnetique emanant d'un sujet et sa variation

Country Status (6)

Country Link
US (1) US20090137895A1 (fr)
EP (1) EP1996074A4 (fr)
JP (1) JP5155193B2 (fr)
KR (1) KR100794721B1 (fr)
CN (1) CN101410054A (fr)
WO (1) WO2007100220A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981399A1 (fr) * 2006-02-10 2008-10-22 Sang Moon Lee Capteur de détection de signal électro-magnétique biologique et son dispositif de diagnostic

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742888B2 (en) 2005-12-08 2014-06-03 Electronics And Telecommunications Research Institute Communication apparatus having human body contact sensing function and method thereof
KR100917607B1 (ko) * 2007-09-21 2009-09-17 한국전자통신연구원 인체 통신 장치
KR100842250B1 (ko) 2005-12-08 2008-06-30 한국전자통신연구원 인체접촉 감지를 이용하는 통신 장치 및 그 방법
KR100866545B1 (ko) * 2007-02-06 2008-11-03 연세대학교 산학협력단 비접촉 방식의 착용형 무선 생체신호 측정 시스템
KR100933569B1 (ko) * 2008-04-21 2009-12-29 서울여자대학교 산학협력단 조직병리영상 및 자기공명영상을 이용한 전립선암 진단방법 및 장치
BG111298A (bg) * 2012-08-29 2014-02-28 Юрий МАРКОВ Система и метод за въздействие върху строежа на веществата чрез ниско енергийно модулирано магнитно поле
KR101739656B1 (ko) 2015-11-23 2017-05-24 이경호 핸디형 유방암 검진기
KR101904431B1 (ko) 2016-01-26 2018-10-08 (주)피지오랩 디지털 생체전기신호 센서 시스템
KR101962277B1 (ko) * 2018-07-24 2019-03-26 한화시스템(주) 야전시험장비 시스템
CN110974216B (zh) * 2019-12-20 2022-06-03 首都医科大学宣武医院 一种无线心电监护传感器的遥控系统
WO2023129510A1 (fr) * 2021-12-27 2023-07-06 Emulate Therapeutics, Inc. Mécanisme d'administration non intrusif pour produire des effets physiologiques dans des organismes vivants

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6580942B1 (en) * 1999-04-07 2003-06-17 Healthcare Technology Limited Heart activity detection apparatus
US20040111042A1 (en) 2002-12-09 2004-06-10 Imre Szabo Bioelectric telemetering system and method
US20060029925A1 (en) * 2002-12-12 2006-02-09 Lee Sang M Solid bio-material for a sensor that detects bio-electric signals through the use of the characteristics and functions of bio-epidermal tissues and epidermal tissues of living organisms and the methods for producing the same
KR20060050892A (ko) * 2004-08-31 2006-05-19 재단법인서울대학교산학협력재단 전기적 비접촉 심전도 측정장치 및 그에 따른 측정방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4329898A1 (de) * 1993-09-04 1995-04-06 Marcus Dr Besson Kabelloses medizinisches Diagnose- und Überwachungsgerät
AU1989100A (en) * 1999-01-05 2000-07-24 Kaiku Limited Impedance measurements of bodily matter
EP1135052A1 (fr) * 1999-02-12 2001-09-26 Cygnus, Inc. Dispositifs et procedes permettant d'effectuer des mesures frequentes d'un analyte present dans un systeme biologique
US6913877B1 (en) * 2000-09-11 2005-07-05 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for detecting bioactive compounds
US6863833B1 (en) * 2001-06-29 2005-03-08 The Board Of Trustees Of The Leland Stanford Junior University Microfabricated apertures for supporting bilayer lipid membranes
US20040100376A1 (en) * 2002-11-26 2004-05-27 Kimberly-Clark Worldwide, Inc. Healthcare monitoring system
JP2005095307A (ja) 2003-09-24 2005-04-14 Matsushita Electric Ind Co Ltd 生体センサおよびこれを用いた支援システム
US20050090754A1 (en) * 2003-09-08 2005-04-28 Wolff Steven B. Body worn latchable wireless medical computing platform
JP4633374B2 (ja) 2004-03-10 2011-02-16 公立大学法人会津大学 生体センサ装置
US8361165B2 (en) * 2004-06-28 2013-01-29 Alfred E. Mann Foundation For Scientific Research Neural prosthetic with touch-like sensing
WO2006014810A2 (fr) * 2004-07-29 2006-02-09 Kevin Ferguson Systeme de mesure de mouvement humain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6580942B1 (en) * 1999-04-07 2003-06-17 Healthcare Technology Limited Heart activity detection apparatus
US20040111042A1 (en) 2002-12-09 2004-06-10 Imre Szabo Bioelectric telemetering system and method
US20060029925A1 (en) * 2002-12-12 2006-02-09 Lee Sang M Solid bio-material for a sensor that detects bio-electric signals through the use of the characteristics and functions of bio-epidermal tissues and epidermal tissues of living organisms and the methods for producing the same
KR20060050892A (ko) * 2004-08-31 2006-05-19 재단법인서울대학교산학협력재단 전기적 비접촉 심전도 측정장치 및 그에 따른 측정방법

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1996074A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981399A1 (fr) * 2006-02-10 2008-10-22 Sang Moon Lee Capteur de détection de signal électro-magnétique biologique et son dispositif de diagnostic
EP1981399A4 (fr) * 2006-02-10 2010-01-13 Sang Moon Lee Capteur de détection de signal électro-magnétique biologique et son dispositif de diagnostic

Also Published As

Publication number Publication date
EP1996074A4 (fr) 2010-06-16
JP5155193B2 (ja) 2013-02-27
KR100794721B1 (ko) 2008-01-15
EP1996074A1 (fr) 2008-12-03
KR20070090412A (ko) 2007-09-06
US20090137895A1 (en) 2009-05-28
CN101410054A (zh) 2009-04-15
JP2009528122A (ja) 2009-08-06

Similar Documents

Publication Publication Date Title
US20090137895A1 (en) Real-time diagnostic system employing non-invasive method to analyze electro-magnetic field radiated from a subject and the variation thereof
CA2134423C (fr) Appareillage et methode de typage tissulaire
EP1219241A1 (fr) Stethoscope
WO2009027868A1 (fr) Quantification de l'allaitement
US7096126B2 (en) Method and device for detecting functional and metabolic data of a living organism
CN113133753A (zh) 基于磁感应相位移的生物组织血流实时监测系统及模拟监测系统
KR101829474B1 (ko) 몸 부위 등별 중량 변동 측정 시스템, 측정 방법, 그 이용 시스템 및 이용 방법
CN1287727C (zh) 全消化道吞服式遥测胶囊体外电磁励磁式定位系统
CN111012329A (zh) 一种高精度、运动型、无创便携式心肺功能参数测量设备
CN113786211B (zh) 一种超声红细胞聚集度检测调控系统
JP3182601B2 (ja) 組織タイプ認識方法およびそのための装置
US9364159B2 (en) Sensor for detecting biological electro-magnetic signal and the diagnostic device using the same
CN106937866A (zh) 一种全科医生用的生理参数测量仪
ES2856009T3 (es) Sistema y método de análisis de la presión arterial
RU100899U1 (ru) Устройство для определения степени подвижности зуба
HUP0002273A2 (hu) Berendezés-rendszer gyógykezelés alatt álló egyének vizsgálatára és/vagy terápiájuk előkészítésére
KR102389849B1 (ko) Mra와 인체 임피던스 스팩트럼 분석을 통한 영양소 측정장치
RU2543293C2 (ru) Устройство для контроля физиологических параметров человека
CN214284939U (zh) 一种高精度、运动型、无创便携式心肺功能参数测量设备
CN106667437A (zh) 一种预测植入式医疗设备手术后并发症的系统
CN102697511A (zh) 体内探测智能针头系统
US20130261420A1 (en) System and method for non-invasive diagnostic of mammals
Yu et al. VerteMeasure: An Efficient Spinal Bone Impedance Measuring System for Surgery Assistance
WO2011135386A1 (fr) Appareil pour la détermination et le stockage du niveau d'agitation d'un individu humain comprenant des électrodes d'électrocardiogramme (ecg) et un dispositif de surveillance de résistance de la peau
RU2324421C2 (ru) Устройство для проведения тестирования физиологической реакции пациента

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 200780007434.2

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008557212

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12280766

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2007715450

Country of ref document: EP